Nothing Special   »   [go: up one dir, main page]

Dawar et al., 2023 - Google Patents

P1. 23-03 Amplicon-Based Liquid Biopsy Prospectively Detects More Tissue-Confirmed Guideline-Recommended Biomarkers in Lung Cancer

Dawar et al., 2023

View PDF
Document ID
3406720945663136548
Author
Dawar R
Carney J
Orsini J
Scilla K
Lopes G
Tan M
Tan Y
Chin T
Toh C
Goh B
Samol J
Publication year
Publication venue
Journal of Thoracic Oncology

External Links

Snippet

Methods LIQUIK (LIQUId Biopsy for Detection of Actionable Genomic BiomarKers in Patients with Advanced Non-small Cell Lung Cancer; NCT04703153) is a prospective multi-center international study comparing different liquid biopsies with conventional tissue genotyping …
Continue reading at www.jto.org (PDF) (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G01N33/574—Immunoassay; Biospecific binding assay for cancer
    • G01N33/57407—Specifically defined cancers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/487—Physical analysis of biological material of liquid biological material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Hybridisation probes
    • C12Q1/6883—Hybridisation probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Hybridisation probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N27/00—Investigating or analysing materials by the use of electric, electro-chemical, or magnetic means
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume, or surface-area of porous materials
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N25/00—Investigating or analyzing materials by the use of thermal means
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Detecting, measuring or recording for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications

Similar Documents

Publication Publication Date Title
Russo et al. The molecular profiling of solid tumors by liquid biopsy: A position paper of the AIOM–SIAPEC-IAP–SIBioC–SIC–SIF Italian Scientific Societies
Cheung et al. Latest development of liquid biopsy
Khoja et al. Biomarker utility of circulating tumor cells in metastatic cutaneous melanoma
Harada et al. Rare molecular subtypes of lung cancer
Crowley et al. Liquid biopsy: monitoring cancer-genetics in the blood
US10697967B2 (en) Methods for predicting response of triple-negative breast cancer to therapy
JP2017184729A5 (en)
Gao et al. Elevated serum CEA levels are associated with the explosive progression of lung adenocarcinoma harboring EGFR mutations
Wei et al. Circulating DNA addresses cancer monitoring in non small cell lung cancer patients for detection and capturing the dynamic changes of the disease
JP2008533487A (en) Methods to predict progression-free and overall survival at each follow-up period point during therapy for patients with metastatic breast cancer using circulating tumor cells
Gedvilaitė et al. Cell-free DNA in non-small cell lung cancer
Sun et al. Use of liquid biopsy in monitoring colorectal cancer progression shows strong clinical correlation
Ruggiero et al. Identification of a miRNA-based non-invasive predictive biomarker of response to target therapy in BRAF-mutant melanoma
Zhu et al. A subset of esophageal squamous cell carcinoma patient-derived xenografts respond to cetuximab, which is predicted by high EGFR expression and amplification
Ren et al. A narrative review of primary research endpoints of neoadjuvant therapy for lung cancer: past, present and future
WO2017094805A1 (en) Method for evaluating efficacy of treatment for malignant neoplasm by measuring amount of ctdna
CN111133312A (en) Methods for diagnosing and treating lung cancer
Nagakubo et al. Nucleic acid quality assessment is critical to the success of the Oncomine Dx target test for lung cancer
Dawar et al. P1. 23-03 Amplicon-Based Liquid Biopsy Prospectively Detects More Tissue-Confirmed Guideline-Recommended Biomarkers in Lung Cancer
O'Byrne et al. P1. 23-04 Extracellular Small Vesicle Phosphorylated PD-L1 Liquid Biopsy Levels Correlate with Tumour Proportion Score (TPS) in NSCLC
EP2809798B1 (en) Method and apparatus for detecting cancer in mammals
Patel et al. Examining EML4-ALK variants in the clinical setting: the next frontier?
Batra et al. P1. 23-02 Circulating Tumour DNA as a Predictive Biomarker for Tumour Response and Prolonged Clinical Benefit with Nivolumab in NSCLC
Jones et al. Performance of standardized BEAMing platform for detecting RAS mutations in the blood of metastatic colorectal cancer (mCRC) patients
Qui et al. Analysis of plasma HER2 copy number in cell-free DNA of breast cancer patients: a comparison with HER2 extracellular domain protein level in serum